Haisco licenses inflammatory drug to Sentivera for $40M upfront, $36M stock, $1.46B milestones; FDA OKs ViiV's dolutegravir for newborns; Noetik hits GSK milestone.
August 26, 2026 11:16 AM EDT
News Briefing
Haisco grants license to Sentivera; ViiV's HIV treatment OK'd for newborns
Haisco Pharmaceutical licenses inflammatory disease drug to Sentivera: The Chinese biotech is granting ex-China rights for the unnamed candidate to US startup
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children
FDA extends approval of Tivicay to treat newborns with HIV
Gilead christens Bixlenvo with FDA nod for new HIV treatment combo tablet
FDA Expands Label of Oral HIV Drug to Newborns
U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children
Haisco Pharma partners with ARCH Venture's Bob Nelsen & Population Health Partners' Clive Meanwell to launch Sentivera in a…
Gilead-Merck detail Phase 3 HIV data, Dimension Capital closes $800M fund, WuXi AppTec fights DoD blacklist bid, and more.
The FDA has extended its approval of dolutegravir tablets for oral suspension to treat newborns with HIV. Dolutegravir tablets…
Vertex's Casgevy wins pediatric approval, United Therapeutics buys Thymmune for up to $300M, plus deals from Insilico, Fosun and…
Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed patients &…
